Open industry challenge: if any competing migration tool achieves even 30% accuracy on your dashboards, they will complete your entire enterprise migration free Pulse Convert doesn’t just migrate ...
Masimo Corporation (Nasdaq: MASI) (“Masimo”), a leading global innovator in patient monitoring, today announced that its stockholders voted in favor of the proposal to adopt the previously announced ...
Masimo (NASDAQ: MASI) today announced the findings of a study evaluating the accuracy of Masimo SET ® pulse oximetry among critically ill neonates and demonstrating less than 1% overall statistical ...
These promising results—from an NIH-funded study that exclusively evaluated Masimo SET ® in a vulnerable, clinically fragile patient population—add to previously published evidence of its strong ...
NICU Study Adds to the Evidence Demonstrating SET®’s Accuracy in Challenging Real-World Settings, With No Clinically Significant Differences in Performance Across Skin Pigmentation Categories or Race ...
Masimo Corp. today reported study data showing that its pulse oximetry technology accurately monitored hospitalized newborns of all skin tones without dangerous drops in blood oxygen. The findings ...
Apple has been embroiled in a six-year legal battle over one of its Apple Watch health apps. The end may finally be in sight, and here's what Apple has to say about it. Anna Gragert Senior Editor, ...
The USITC has denied a request by Masimo to reinstate a ban on the Apple Watch, closing its case on alleged blood oxygen patent infringement. The long-running lawsuit over the Apple Watch has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results